OCI-Ly7Homo sapiens (Human)Cancer cell line
Also known as: LY7, Ly7, OCILY7, OCI-Ly07, OCI-Ly 7, Oci-Ly-7, OCI-Ly-7, OCI-LY-7, OCI-LY7
Quick Overview
Human B-cell lymphoma cell line for cancer research
Detailed Summary
Basic Information
| Database ID | CVCL_1881 |
|---|---|
| Species | Homo sapiens (Human) |
| Tissue Source | Peripheral blood[UBERON:UBERON_0000178] |
Donor Information
| Age | 48 |
|---|---|
| Age Category | Adult |
| Sex | Male |
Disease Information
| Disease | Diffuse large B-cell lymphoma |
|---|---|
| Lineage | Lymphoid |
| Subtype | Diffuse Large B-Cell Lymphoma, NOS |
| OncoTree Code | DLBCLNOS |
DepMap Information
| Source Type | DSMZ |
|---|---|
| Source ID | ACH-001617_source |
Known Sequence Variations
| Type | Gene/Protein | Description | Zygosity | Note | Source |
|---|---|---|---|---|---|
| Gene fusion | IGH | MYC-IGH | - | - | PubMed=31160637 |
Haplotype Information (STR Profile)
Short Tandem Repeat (STR) profile for cell line authentication.
Loading gene expression data...
Publications
Pan-cancer proteomic map of 949 human cell lines.";
Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
Cancer Cell 40:835-849.e8(2022).
The LL-100 panel: 100 cell lines for blood cancer studies.";
MacLeod R.A.F., Nagel S., Steube K.G., Uphoff C.C., Drexler H.G.
Sci. Rep. 9:8218-8218(2019).
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
Cancer Res. 79:1263-1273(2019).
Characterization of human cancer cell lines by reverse-phase protein arrays.
Liang H.
Cancer Cell 31:225-239(2017).
Subclones in B-lymphoma cell lines: isogenic models for the study of gene regulation.
Zaborski M., Drexler H.G.
Oncotarget 7:63456-63465(2016).
A landscape of pharmacogenomic interactions in cancer.";
Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
Cell 166:740-754(2016).
A catalog of HLA type, HLA expression, and neo-epitope candidates in human cancer cell lines.
Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.
OncoImmunology 3:e954893.1-e954893.12(2014).
A comprehensive transcriptional portrait of human cancer cell lines.
Settleman J., Seshagiri S., Zhang Z.-M.
Nat. Biotechnol. 33:306-312(2015).
Mutational and structural analysis of diffuse large B-cell lymphoma using whole-genome sequencing.
Marra M.A.
Blood 122:1256-1265(2013).
Genetic heterogeneity of diffuse large B-cell lymphoma.";
Dunson D.B., Dave S.S.
Proc. Natl. Acad. Sci. U.S.A. 110:1398-1403(2013).
MCL1 is deregulated in subgroups of diffuse large B-cell lymphoma.";
Hernandez-Ilizaliturri F.J., Tzankov A., Lenz G.
Leukemia 27:1381-1390(2013).
Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma.
Kutok J.L., Shipp M.A.
Blood 116:3268-3277(2010).
Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma.
Cook J.R., Weisenburger D.D., Chan W.-C., Pierce S.K., Staudt L.M.
Nature 463:88-92(2010).
Expression of the ULBP ligands for NKG2D by B-NHL cells plays an important role in determining their susceptibility to rituximab-induced ADCC.
Mori F., Ding J.-M., Komatsu H., Iida S., Ueda R.
Int. J. Cancer 125:212-221(2009).
Copy number abnormalities, MYC activity, and the genetic fingerprint of normal B cells mechanistically define the microRNA profile of diffuse large B-cell lymphoma.
Robetorye R.S., Aguiar R.C.T.
Blood 113:6681-6690(2009).
Identification and characterization of a novel gene, C13orf25, as a target for 13q31-q32 amplification in malignant lymphoma.
Yoshida Y., Seto M.
Cancer Res. 64:3087-3095(2004).
Molecular cytogenetic characterization of non-Hodgkin lymphoma cell lines.
Mehra S., Messner H.A., Minden M.D., Chaganti R.S.K.
Genes Chromosomes Cancer 33:225-234(2002).
p53 mutations, c-myc and bcl-2 rearrangements in human non-Hodgkin's lymphoma cell lines.
Chang H., Blondal J.A., Benchimol S., Minden M.D., Messner H.A.
Leuk. Lymphoma 19:165-171(1995).